Aurora Cannabis Inc. (ACB)
USD 4.25
(-0.7%)
USD 4.25
(-0.7%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 104.79 Million CAD | -53.94% |
| 2022 | 227.52 Million CAD | -15.57% |
| 2021 | 269.49 Million CAD | -32.55% |
| 2020 | 399.55 Million CAD | -24.79% |
| 2019 | 531.24 Million CAD | -17.61% |
| 2018 | 644.82 Million CAD | 217.32% |
| 2017 | 203.21 Million CAD | 218.08% |
| 2016 | 63.88 Million CAD | 509.23% |
| 2015 | 10.48 Million CAD | 25.28% |
| 2014 | 8.37 Million CAD | 1572.65% |
| 2013 | 500.43 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | 104.79 Million CAD | 1.4% |
| 2023 FY | 104.79 Million CAD | -53.94% |
| 2023 Q1 | 127.01 Million CAD | -52.87% |
| 2023 Q2 | 103.34 Million CAD | -18.64% |
| 2022 Q4 | 269.49 Million CAD | 18.45% |
| 2022 Q3 | 227.52 Million CAD | 0.64% |
| 2022 Q2 | 226.07 Million CAD | -30.56% |
| 2022 FY | 227.52 Million CAD | -15.57% |
| 2022 Q1 | 325.56 Million CAD | 20.81% |
| 2021 Q1 | 406.77 Million CAD | 1.81% |
| 2021 Q2 | 414.45 Million CAD | 1.89% |
| 2021 Q3 | 388.14 Million CAD | -6.35% |
| 2021 Q4 | 269.49 Million CAD | -30.57% |
| 2021 FY | 269.49 Million CAD | -32.55% |
| 2020 Q4 | 399.55 Million CAD | -16.92% |
| 2020 Q3 | 480.91 Million CAD | -2.52% |
| 2020 Q2 | 493.37 Million CAD | -2.7% |
| 2020 Q1 | 507.04 Million CAD | -4.56% |
| 2020 FY | 399.55 Million CAD | -24.79% |
| 2019 Q2 | 602.12 Million CAD | -24.33% |
| 2019 Q1 | 795.72 Million CAD | 23.4% |
| 2019 FY | 531.24 Million CAD | -17.61% |
| 2019 Q3 | 592.71 Million CAD | -1.56% |
| 2019 Q4 | 531.24 Million CAD | -10.37% |
| 2018 Q3 | 639.1 Million CAD | 83.88% |
| 2018 FY | 644.82 Million CAD | 217.32% |
| 2018 Q4 | 644.82 Million CAD | 0.9% |
| 2018 Q2 | 347.55 Million CAD | 19.39% |
| 2018 Q1 | 291.1 Million CAD | 43.25% |
| 2017 Q3 | 209.17 Million CAD | 65885.17% |
| 2017 Q4 | 203.21 Million CAD | -2.85% |
| 2017 FY | 203.21 Million CAD | 218.08% |
| 2017 Q1 | 66.91 Million CAD | 4.74% |
| 2017 Q2 | 317 Thousand CAD | -99.53% |
| 2016 Q4 | 63.88 Million CAD | 240.01% |
| 2016 Q1 | 13.52 Million CAD | 28.98% |
| 2016 Q2 | 20.61 Million CAD | 52.43% |
| 2016 Q3 | 18.78 Million CAD | -8.86% |
| 2016 FY | 63.88 Million CAD | 509.23% |
| 2015 FY | 10.48 Million CAD | 25.28% |
| 2015 Q3 | 9.88 Million CAD | 5.29% |
| 2015 Q1 | 9.3 Million CAD | 11.2% |
| 2015 Q2 | 9.39 Million CAD | 0.88% |
| 2015 Q4 | 10.48 Million CAD | 6.06% |
| 2014 Q4 | 8.37 Million CAD | 240.19% |
| 2014 FY | 8.37 Million CAD | 1572.65% |
| 2014 Q1 | 400 Thousand CAD | -20.07% |
| 2014 Q3 | 2.46 Million CAD | 3.1% |
| 2014 Q2 | 2.38 Million CAD | 496.66% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | 500.43 Thousand CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | 500.43 Thousand CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 84.459% |
| Embecta Corp. | 1.63 Billion USD | 93.604% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 66.768% |
| Dynavax Technologies Corporation | 256.91 Million USD | 59.212% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 80.628% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 82.119% |
| PainReform Ltd. | 86 Thousand USD | -121750.0% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -6.04% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -15832.827% |
| SCYNEXIS, Inc. | 15.08 Million USD | -594.901% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -3858.179% |
| Cosmos Health Inc. | 12.42 Million USD | -743.459% |
| Journey Medical Corporation | 17.73 Million USD | -491.038% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -15832.827% |
| Safety Shot Inc | 1.54 Million USD | -6665.188% |
| Alpha Teknova, Inc. | 30.45 Million USD | -244.051% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -518.674% |
| Bright Green Corporation | 1.85 Million USD | -5558.924% |
| Procaps Group, S.A. | 285.93 Million USD | 63.351% |
| Theratechnologies Inc. | 58.96 Million USD | -77.708% |
| Harrow Health, Inc. | 190.5 Million USD | 44.992% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -17135.362% |
| Biofrontera Inc. | 5.39 Million USD | -1840.934% |
| DURECT Corporation | 20.74 Million USD | -405.114% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -152.344% |
| Cronos Group Inc. | 2.53 Million USD | -4025.731% |
| OptiNose, Inc. | 131.74 Million USD | 20.462% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 85.355% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -188.498% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -8833.543% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 12.199% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -468.636% |
| Radius Health, Inc. | 365.31 Million USD | 71.315% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -1811.388% |
| ProPhase Labs, Inc. | 21.38 Million USD | -390.136% |
| Phibro Animal Health Corporation | 525.45 Million USD | 80.057% |
| Procaps Group S.A. | 285.93 Million USD | 63.351% |
| Alvotech | 1.07 Billion USD | 90.256% |
| TherapeuticsMD, Inc. | 8 Million USD | -1209.069% |
| Viatris Inc. | 18.12 Billion USD | 99.422% |
| Rockwell Medical, Inc. | 13.43 Million USD | -679.753% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -592.65% |
| SIGA Technologies, Inc. | 1.46 Million USD | -7057.811% |
| Tilray Brands, Inc. | 387.31 Million USD | 72.944% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 19.614% |
| Shineco, Inc. | 29.65 Million USD | -253.35% |
| PetIQ, Inc. | 468.3 Million USD | 77.623% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -175115.276% |
| Incannex Healthcare Limited | 373 Thousand USD | -27994.102% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 75.539% |
| Alimera Sciences, Inc. | 67.39 Million USD | -55.479% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 40.91 Million USD | -156.138% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -9534.235% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -1166.113% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -4921.131% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -10043.208% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -196.154% |
| Hempacco Co., Inc. | 13.72 Million USD | -663.532% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.07 Billion USD | 90.256% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | -67.757% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 83.015% |
| Currenc Group, Inc. | 31.94 Million USD | -228.05% |
| Kamada Ltd. | 8.74 Million USD | -1097.75% |
| Indivior PLC | 281.6 Million USD | 62.788% |
| Evoke Pharma, Inc. | 5 Million USD | -1995.82% |
| Flora Growth Corp. | 3.67 Million USD | -2753.785% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -10043.208% |
| Evolus, Inc. | 126.54 Million USD | 17.191% |
| HUTCHMED (China) Limited | 86.13 Million USD | -21.665% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 83.197% |
| Akanda Corp. | 3.99 Million USD | -2520.567% |